Clinical Development at the World Orphan Drug Congress

 

Strategy, advocacy and partnering for the orphan drug industry

2-5 November 2020

Melia Sitges Hotel Resort, Barcelona, Spain

 

 
700+
Attendees
350+
Companies
200+
Speakers
80%
Decision Makers
2
Co-located events

Clinical Development

 

➤  Covering all aspects in patient centricity & trial design

➤  The use of biomarkers to support clinical success

➤  Optimizing the transition from translational science to clinical development in rare disease

➤  How technology and patient-focused approaches can accelerate clinical development

➤  How to build new models to run natural history studies and registries with perspectives from the EMA, Pharma, biotech and patients

2019 KEY SPEAKERS

 

George Jeha , Medical Director, Rare Disease , BioMarin Pharmaceutical Inc.

George Jeha | Medical Director, Rare Disease | BioMarin Pharmaceutical Inc. » speaking at Orphan Drug Congress

Prof Kassim Javaid , Associate Professor, University Lecturer In Metabolic Bone Disease , Oxford University Hospitals N.H.S. Trust

Prof Kassim Javaid | Associate Professor, University Lecturer In Metabolic Bone Disease | Oxford University Hospitals N.H.S. Trust » speaking at Orphan Drug Congress

Martine Zimmermann , Senior Vice President, Head of Global Regulatory Affairs , Alexion Pharmaceuticals

Martine Zimmermann | Senior Vice President, Head of Global Regulatory Affairs | Alexion Pharmaceuticals » speaking at Orphan Drug Congress

Kristina Larsson , Head Of Orphan Drugs , EMA

Kristina Larsson | Head Of Orphan Drugs | EMA » speaking at Orphan Drug Congress

Amy Gray , Chief Executive Officer , Charcot-Marie-Tooth Association

Amy Gray | Chief Executive Officer | Charcot-Marie-Tooth Association » speaking at Orphan Drug Congress

Scott Schliebner , Vice President, Scientific Affairs, Rare Diseases , PRA Health Sciences

Scott Schliebner | Vice President, Scientific Affairs, Rare Diseases | PRA Health Sciences » speaking at Orphan Drug Congress